Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-α in patients with metastatics renal cell carcinoma: Results of an open single-armed multicentre phase II study

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 441-449

  Donskov, F ^a   Von Der Maase, H ^a   Henriksson, R ^b   Stierner, U ^c   Wersall P ^d   Nellemann, H ^e   Hellstrand, K ^a   Engman, K ^a   Naredi, P ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Department of Umbilicus Nordica ^*  (Sweden)

Author keywords

Histamine; Inferferon ; Interleukin 2; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; CIMETIDINE; CORTICOSTEROID; DIMAPRIT; FUROSEMIDE; GLYCOSAMINOGLYCAN POLYSULFATE; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON ALFANATIVE; INTERLEUKIN 2; LOPERAMIDE; METOCLOPRAMIDE; OMEPRAZOLE; ONDANSETRON; PARACETAMOL; RANITIDINE; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 2; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALAISE; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCLE CRAMP; MYXEDEMA; NAUSEA; NEPHRECTOMY; NEUROLOGIC DISEASE; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; COMPUTER ASSISTED TOMOGRAPHY; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTAMINE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OUTPATIENTS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036018911     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf049     Document Type: Article

References (35)

1. Cancer statistics, 1999
2. Chemotherapy for renal cell carcinoma
3. Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2
4. Systemic therapy for renal cell carcinoma
5. Immunotherapy of renal cell carcinoma
6. Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up
7. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
8. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe
9. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
10. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma
11. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with TIL phenotype and function
12. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
13. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites
14. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors
15. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2
16. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites
17. Histamine protects T cells and natural killer cells against oxidative stress
18. Histamine H2-receptor-mediated regulation of human natural killer cell activity
19. Regulation of the natural killer cell response to interferon-alpha by biogenic amines
20. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice
21. Role of histamine in natural killer cell-mediated resistance against tumor cells
22. Histamine and cytokine therapy
23. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia
24. Histamine dihydrochloride, interleukin-2 and interferon-alfa in multiple myeloma
25. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
26. Renal cell carcinoma: Natural history and results of treatment
27. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
28. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
29. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
30. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place
31. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma
32. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma
33. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma
34. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen
35. Recombinant interleukin-2 in metastatic renal cell carcinoma - A European multicentre phase II study